Literature DB >> 22814701

Red blood cell lysate modulates the expression of extracellular matrix proteins in dermal fibroblasts.

Amir Akbari1, Yunyuan Li, Ruhangiz T Kilani, Aziz Ghahary.   

Abstract

During the early stage of wound healing process, blood clots can be served as a temporary extracellular matrix (ECM) to let skin cell migration and proliferation. The red blood cells are generally thought as inert bystanders in the early and inflammatory phase of wound healing. Here, we provide evidence that red blood cells (RBC) also play an important role in modulation of key ECM components such as type-I collagen, α-smooth muscle actin, fibronectin, and matrix metalloproteinases (MMPs). In this study, we used western blot analysis and showed a significant increase in the level of MMP-1, 2, 3. Furthermore, we found that RBC lysate significantly down-regulates type-I collagen and α-smooth muscle actin while up-regulates fibronectin expression in dermal fibroblasts. To further explore the mechanism by which RBC lysate modulates MMP-1 expression, the effect of inhibitors for three MAPK signaling pathways on RBC inducing MMP-1 expression by dermal fibroblasts were tested. The result showed that the inhibitor of ERK1/2 could abrogate the stimulatory effect of RBC lysate on MMP-1 expression in dermal fibroblasts. Consistently, RBC treatment results in an increase of ERK1/2 phosphorylation in dermal fibroblast. In conclusion, these findings suggest that RBC lysate can modulate the expression of MMPs and key ECM components which are important in healing process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814701     DOI: 10.1007/s11010-012-1400-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

Review 1.  Cutaneous wound healing.

Authors:  A J Singer; R A Clark
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

2.  Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds.

Authors:  M S Agren
Journal:  Arch Dermatol Res       Date:  1999-11       Impact factor: 3.017

3.  Effects of haemorrhage upon surgical operations.

Authors:  F P McGinn
Journal:  Br J Surg       Date:  1976-10       Impact factor: 6.939

4.  Red blood cell proteomics.

Authors:  E M Pasini; M Mann; A W Thomas
Journal:  Transfus Clin Biol       Date:  2010-07-23       Impact factor: 1.406

5.  Trauma-hemorrhage delays wound healing potentially by increasing pro-inflammatory cytokines at the wound site.

Authors:  M K Angele; M W Knöferl; A Ayala; J E Albina; W G Cioffi; K I Bland; I H Chaudry
Journal:  Surgery       Date:  1999-08       Impact factor: 3.982

6.  Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity.

Authors:  H Cook; K J Davies; K G Harding; D W Thomas
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

7.  Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1.

Authors:  M Brauchle; D Glück; F Di Padova; J Han; H Gram
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

8.  Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction.

Authors:  R Manabe; N Oh-e; K Sekiguchi
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

9.  RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components.

Authors:  Anastasios G Kriebardis; Marianna H Antonelou; Konstantinos E Stamoulis; Effrosini Economou-Petersen; Lukas H Margaritis; Issidora S Papassideri
Journal:  Transfusion       Date:  2008-06-28       Impact factor: 3.157

10.  Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan.

Authors:  Andres F Muro; Anil K Chauhan; Srecko Gajovic; Alessandra Iaconcig; Fabiola Porro; Giorgio Stanta; Francisco E Baralle
Journal:  J Cell Biol       Date:  2003-07-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.